Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.